The N-glycosylation of immunoglobulin G as a novel biomarker of Parkinson's disease

Glycobiology

Volumn 27, Issue 5, 2017, Pages 501-510

  Russell, Alyce C ^a   Šimurina, Mirna ^b   Garcia, Monique T ^a   Novokmet, Mislav ^c   Wang, Youxin ^d   Rudan, Igor ^e   Campbell, Harry ^e   Lauc, Gordan ^a,b,c   Thomas, Meghan G ^a   Wang, Wei ^a,d  

^a EDITH COWAN UNIVERSITY   (Australia)

^b UNIVERSITY OF ZAGREB   (Croatia)

^c GENOS GLYCOSCIENCE RESEARCH LABORATORY   (Croatia)

^d CAPITAL MEDICAL UNIVERSITY   (China)

^e UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

biomarker; glycomics; immunoglobulin G; Parkinson's disease

Indexed keywords

FC RECEPTOR; GLYCAN; IMMUNOGLOBULIN G; BIOLOGICAL MARKER; POLYSACCHARIDE;

AGE; AGED; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BODY MASS; CAUCASIAN; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FUCOSYLATION; HUMAN; HYDROPHILIC INTERACTION CHROMATOGRAPHY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; QUALITY OF LIFE; SEX DIFFERENCE; SIALYLATION; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; BLOOD; DISEASE COURSE; GENETICS; GLYCOBIOLOGY; GLYCOSYLATION; MIDDLE AGED; PATHOLOGY;

AGED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; BIOMARKERS; DISEASE PROGRESSION; FEMALE; GLYCOMICS; GLYCOSYLATION; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PARKINSON DISEASE; POLYSACCHARIDES;

EID: 85017294045     PISSN: 09596658     EISSN: 14602423     Source Type: Journal    
DOI: 10.1093/glycob/cwx022     Document Type: Article

References (50)

1. Akmacic IT, Ventham NT, Theodoratou E, Vuckovic F, Kennedy NA, Krištic J, Nimmo ER, Kalla R, Drummond H, Štambuk J. 2015. inflammatory bowel disease associates with proinflammatory potential of the immunoglobulin g glycome. Inflamm Bowel Dis. 21(6):1237.
2. Arnold JN, Wormald MR, Sim RB, Rudd PM, Dwek RA. 2007. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol. 25:21-50.
3. Biermann M, Griffante G, Podolska M, Boeltz S, Stürmer J, Muñoz L, Bilyy R, Herrmann M. 2016. Sweet but dangerous-the role of immunoglobulin G glycosylation in autoimmunity and inflammation. Lupus. 25(8): 934-942.
4. Böhm S, Schwab I, Lux A, Nimmerjahn F. 2012. The role of sialic acid as a modulator of the anti-inflammatory activity of IgG. Seminars in immunopathol. 34(3):443-453.
5. Braak H, Tredici KD, Rub U, Vos RAId, Steur ENHJ, Braak E. 2003. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiology of Aging. 24(2):197-211.
6. Bucks R, Cruise K, Skinner T, Loftus A, Barker R, Thomas M. 2011. Coping processes and healthrelated quality of life in Parkinson's disease. Int J Geriatr Psychiatry. 26(3):247-255.
7. Chen G, Wang Y, Qin X, Li H, Guo Y, Wang Y, Liu H, Wang X, Song G, Li F. 2013. Change in IgG1 Fc Nlinked glycosylation in human lung cancer: Ageand sexrelated diagnostic potential. Electrophoresis. 34(16):2407-2416.
8. Chen G, Wang Y, Qiu L, Qin X, Liu H, Wang X, Wang Y, Song G, Li F, Guo Y. 2012. Human IgG Fc-glycosylation profiling reveals associations with age, sex, female sex hormones and thyroid cancer. J Proteomics. 75(10):2824-2834.
9. Cooper CA, Gasteiger E, Packer NH. 2001. GlycoMod-a software tool for determining glycosylation compositions from mass spectrometric data. Proteomics. 1(2):340-349.
10. Cruise K, Bucks R, Loftus A, Newton R, Pegoraro R, Thomas M. 2011.Exercise and Parkinson's: Benefits for cognition and quality of life. Acta Neurol Scand. 123(1):13-19.
11. Dall'Olio F, Vanhooren V, Chen CC, Slagboom PE, Wuhrer M, Franceschi C. 2013. N-glycomic biomarkers of biological aging and longevity: A link with inflammaging. Ageing Res Rev. 12(2):685-698.
12. Derkinderen P, Rouaud T, Lebouvier T, Des Varannes SB, Neunlist M, De Giorgio R. 2011. Parkinson disease The enteric nervous system spills its guts. Neurology. 77(19):1761-1767.
13. Ferrara C, Grau S, Jäger C, Sondermann P, Brünker P, Waldhauer I, Hennig M, Ruf A, Rufer AC, Stihle M. 2011. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcRIII and antibodies lacking core fucose. Proc Natl Acad Sci. 108(31):12669-12674.
14. Gindzienska-Sieskiewicz E, Klimiuk PA, Kisiel DG, Gindzienski A, Sierakowski S. 2007. The changes in monosaccharide composition of immunoglobulin G in the course of rheumatoid arthritis. Clin Rheumatol. 26(5):685-690.
15. Gyoneva S, Davalos D, Biswas D, Swanger SA, GarnierAmblard E, Loth F, Akassoglou K, Traynelis SF. 2014. Systemic inflammation regulates microglial responses to tissue damage in vivo. Glia. 62(8):1345-1360.
16. Hirsch EC, Hunot S. 2009. Neuroinflammation in Parkinson's disease: A target for neuroprotection Lancet Neurol. 8(4):382-397.
17. Knezevic A, Polasek O, Gornik O, Rudan I, Campbell H, Hayward C, Wright A, Kolcic I, O'Donoghue N, Bones J et al. 2009. Variability, heritability, and environmental determinants of human plasma N-glycome. J Proteome Res. 8:694-701.
18. Knezevic A, Rudan I, Lauc G, Gornik O, Polasek O, Pucic M, Redzic I, Novokmet M, Rudd PM, Wright AF, et al. 2010. Effects of aging, body mass index, plasma lipid profiles, and smoking on human plasma Nglycans. Glycobiology. 20(8):959-969.
19. Kodar K, Stadlmann J, Klaamas K, Sergeyev B, Kurtenkov O. 2012. Immunoglobulin G Fc N-glycan profiling in patients with gastric cancer by LC-ESI-MS: Relation to tumor progression and survival. Glycoconj J. 29(1):57-66.
20. Krištic J, Vuckovic F, Menni C, Klaric L, Keser T, Beceheli I, et al. 2014. Glycans Are a Novel Biomarker of Chronological and Biological Ages. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 69(7):779-89.
21. Krapp S, Mimura Y, Jefferis R, Huber R, Sondermann P. 2003. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J Mol Biol. 325(5):979-989.
22. Kuo Y-M, Li Z, Jiao Y, Gaborit N, Pani AK, Orrison BM, Bruneau BG, Giasson BI, Smeyne RJ, Gershon MD. 2010. Extensive enteric nervous system abnormalities in mice transgenic for artificial chromosomes containing Parkinson disease-associated -synuclein gene mutations precede central nervous system changes. Hum Mol Genet. 19(9):1633-1650.
23. Lauc G, Huffman JE, Puc ic M, Zgaga L, Adamczyk B, Mužinic A, Novokmet M, Polašek O, Gornik O, Krištic J. 2013. Loci associated with N-glycosylation of human immunoglobulin G show pleiotropy with autoimmune diseases and haematological cancers. PLoS Genet. 9(1): e1003225.
24. Lu J-P, Knezivic A, Wang Y-X, Rudan I, Campbell H, Zou Z-K, Lan J, Lai Q-X, Wu J-J, He Y, et al. 2011. Screening novel biomarkers for metabolic syndrome by profiling human plasma N-glycans in Chinese han and Croatian populations. J Proteome Res. 10:4959-4969.
25. Lundström SL, Yang H, Lyutvinskiy Y, Rutishauser D, Herukka S-K, Soininen H, Zubarev RA. 2014. Blood Plasma IgG Fc glycans are significantly altered in Alzheimer's disease and progressive mild cognitive impairment. J Alzheimers Dis. 38(3):567-579.
26. Malhotra R, Wormald MR, Rudd PM, Fischer PB, Dwek RA, Sim RB. 1995. Glycosylation changes of IgG associated with rheumatooid arthritis can activate complement via the mannose-binding protein. Nat Med. 1(3): 237-243.
27. Menni C, Keser T, Mangino M, Bell JT, Erte I, Akmac ic I, Vuckovic F, Bakovic MP, Gornik O, McCarthy MI. 2013. Glycosylation of immunoglobulin G: Role of genetic and epigenetic influences. PloSOne. 8(12): e82558
28. Nakajima S, Iijima H, Shinzaki S, Egawa S, Inoue T, Mukai A, Hayashi Y, Kondo J, Akasaka T, Nishida T. 2011. Functional analysis of agalactosyl IgG in inflammatory bowel disease patients. Inflamm Bowel Dis. 17(4): 927-936.
29. Nimmerjahn F, Anthony RM, Ravetch JV. 2007. Agalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity. Proc Natl Acad Sci. 104(20):8433-8437.
30. Niven EB, Deutsch CV. 2012. Calculating a robust correlation coefficient and quantifying its uncertainty. Comput Geosci. 40:1-9.
31. Papachroni KK, Ninkina N, Papapanagiotou A, Hadjigeorgiou GM, Xiromerisiou G, Papadimitriou A, Kalofoutis A, Buchman VL. 2007. Autoantibodies to alphasynuclein in inherited Parkinson's disease. J Neurochem. 101(3):749-756.
32. Parkinson J. 2002. An Essay on the Shaking Palsy. J Neuropsychiatry Clin Neurosci. 14(2):223-236.
33. Perkovic MN, Pucic Bakovic M, Kristic J, Novokmet M, Huffman JE, Vitart V, Hayward C, Rudan I, Wilson JF, Campbell H. 2014. The association between galactosylation of immunoglobulin G and body mass index. Prog Neuro-Psychopharmacol Biol Psychiatry. 48:20-25.
34. Gornik O, Supraha-Goreta S, Wormald MR, Redzic I, et al. 2011. High throughput isolation and glycosylation analysis of IgG-Variability and heritability of the IgG glycome in three isolated human populations. Mol Cell Proteomics. 10(10):M111.010090.
35. R Core Team. 2014. R: A Language and Environment for statistical Computing. Vienna, Austria: R Foundation for Statistical Computing.
36. Reale M, Iarlori C, Thomas A, Gambi D, Perfetti B, Di Nicola M, Onofrj M. 2009. Peripheral cytokines profile in Parkinson's disease. Brain Behav Immun. 23(1):55-63.
37. Russell A, Drozdova A, Wang W, Thomas M. 2014. The impact of dementia development concurrent with Parkinson's disease: A new perspective. CNS Neurol Disord Drug Targets. 13(7):1160-1168.
38. Saldova R, Royle L, Radcliffe CM, Hamid UMA, Evans R, Arnold JN, Banks RE, Hutson R, Harvey DJ, Antrobus R. 2007. Ovarian cancer is associated with changes in glycosylation in both acute-phase proteins and IgG. Glycobiology. 17(12):1344-1356.
39. Sanchez-Guajardo V, Barnum CJ, Tansey MG, Romero-Ramos M. 2013. Neuroimmunological processes in Parkinson's disease and their relation to alpha-synuclein: Microglia as the referee between neuronal processes and peripheral immunity. ASN Neuro. 5(2):113-139.
40. Scallon BJ, Tam SH, McCarthy SG, Cai AN, Raju TS. 2007. Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. Mol Immunol. 44(7):1524-1534.
41. Shade K-TC, Anthony RM. 2013. Antibody Glycosylation and inflammation. Antibodies. 2(3):392-414.
42. Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG, Weikert SH, Presta LG. 2002. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcRIII and antibody-dependent cellular toxicity. J Biol Chem. 277(30):26733-26740.
43. Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, Uchida K, Anazawa H, Satoh M, Yamasaki M, et al. 2003. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem. 278(5): 3466-3473.
44. Takeda S, Sato N, Morishita R. 2014. Systemic inflammation, blood-brain barrier vulnerability and cognitive/non-cognitive symptoms in Alzheimer disease: Relevance to pathogenesis and therapy. Front Aging Neurosci. 6 (171):1-8.
45. Vidarsson G, Dekkers G, Rispens T. 2014. IgG subclasses and allotypes: From structure to effector functions. Front Immunol. 5:520.
46. Vuckovic F, Krištic J, Gudelj I, Teruel M, Keser T, Pezer M, PucicBakovic M, Štambuk J, TrbojevicAkmacic I, Barrios C. 2015. Association of systemic lupus erythematosus with decreased immunosuppressive potential of the IgG glycome. Arthritis Rheumatol. 67(11):2978-2989.
47. Vuckovic F, Theodoratou E, Thaçi K, Timofeeva M, Vojta A, Štambuk J, Puc ic-Bakovic M, Rudd PM, Derek L, Servis D. 2016. IgG glycome in colorectal cancer. Clin Cancer Res. 22(12):3078-3086.
48. Wang Y, Klaric L, Yu X, Thaqi K, Dong J, Novokmet M, Wilson J, Polasek O, Liu Y, Krištic J. 2016. The Association between glycosylation of immunoglobulin G and hypertension: A multiple ethnic cross-sectional study. Medicine. 95(17):e3379.
49. Yu X, Wang Y, Kristic J, Dong J, Chu X, Ge S, Wang H, Fang H, Gao Q, Liu D. 2016. Profiling IgG N-glycans as potential biomarker of chronological and biological ages: A community-based study in a Han Chinese population. Medicine. 95(28):e4112.
50. Zou G, Ochiai H, Huang W, Yang Q, Li C, Wang L-X. 2011. Chemoenzymatic synthesis and Fc receptor binding of homogeneous glycoforms of antibody Fc domain. Presence of a bisecting sugar moiety enhances the affinity of Fc to FcIIIa receptor. J Am Chem Soc. 133(46): 18975-18991.